This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08887/identifier/wikipedia/
n13http://www.rxlist.com/
n14http://linked.opendata.cz/resource/drugbank/drug/DB08887/identifier/kegg-compound/
n20http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB08887/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08887/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08887/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08887
rdf:type
n3:Drug
n3:description
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012.
n3:dosage
n4:271B5ABF-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ballantyne CM, Braeckman RA, Soni PN: Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 May 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23701295 # FDA label
n3:group
approved nutraceutical
n3:halfLife
The half life of EPA is 89 hours.
n3:indication
Icosapent ethyl is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia.
owl:sameAs
n20:DB08887
dcterms:title
Icosapent ethyl
adms:identifier
n8:Ethyl_eicosapentaenoic_acid n9:D01892 n10:52937-001-04 n11:DB08887 n14:C16184
n3:mechanismOfAction
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
n3:patent
n6:8314086 n6:8293728 n6:8298554 n6:8357677 n6:8318715 n6:8293727 n6:8445003 n6:8445013 n6:8431560 n6:8440650 n6:8399446 n6:8188146 n6:8367652 n6:8377920 n6:8426399 n6:8415335
n3:routeOfElimination
Icosapent ethyl is not renally excreted
n3:synonym
Ethyl Eicosapentaenoate Ethyl-EPA Ethyl icosapentate Ethyl-Eicosapentaenoic Acid Vascepa Icosapent ethyl EPA ethyl ester Epadel S
n3:toxicity
Icosapent ethyl is generally well tolerated and adverse effects are unrelated to treatment.
n3:volumeOfDistribution
Steady state volume of distribution of active EPA is 88 L
n17:hasAHFSCode
n18:24-06-92
foaf:page
n13:vascepa-drug.htm n16:icosapent-ethyl.html
n3:IUPAC-Name
n5:271B5AC4-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5ACA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5AC9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5AC6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5AC7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5AC8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5AC2-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5AC0-363D-11E5-9242-09173F13E4C5 n5:271B5AC3-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5AC1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n5:271B5AD0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5AD1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5ACB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5ACC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5ACE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5ACD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5ACF-363D-11E5-9242-09173F13E4C5
n3:absorption
Icosapent ethyl is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
86227-47-6
n3:category
n3:clearance
Total plasma clearance, EPA = 684 mL/hr
n3:Bioavailability
n5:271B5AD5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5AD7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5AD8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5AD4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5AD3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5AD6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5AC5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5AD2-363D-11E5-9242-09173F13E4C5